This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $129.99 in the latest trading session, marking a +0.47% move from the prior day.
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis
by Zacks Equity Research
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.
Mallinckrodt Up on Settlement Agreement With Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.
Opioid Overdose Crisis in US Likely to Affect These 3 Stocks
by Sreyoshi Mukherjee
Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.
Johnson & Johnson (JNJ) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $131.55, moving -0.14% from the previous trading session.
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet
by Zacks Equity Research
The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive
by Zacks Equity Research
Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)
by Zacks Equity Research
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate
Trovagene's Onvansertib Shows Response in Phase Ib AML Study
by Zacks Equity Research
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
by Kinjel Shah
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
Bull of the Day: Amgen (AMGN)
by David Borun
One of the world's original biotech companies is still on top of the heap after almost 40 years.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
by Zacks Equity Research
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
by Sreyoshi Mukherjee
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
Top Stock Reports for Johnson & Johnson, Boeing & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Broadcom (AVGO).
Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $129.64, moving +0.08% from the previous trading session.
Should You Buy Vegan Stocks & ETF?
by Neena Mishra
Beyond Meat is one of the hottest IPOs this year and a new ETF aims to capitalize on the trend.
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
by Zacks Equity Research
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
by Zacks Equity Research
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
by Zacks Equity Research
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.